Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01280721

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial

Official title:
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Clinical Trial Summary

ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01280721
Study type Interventional
Source Otsuka Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date November 2010
Completion date August 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02964273 - Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) Phase 3
Terminated NCT01223755 - Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency Phase 2/Phase 3
Completed NCT01214421 - Tolvaptan Extension Study in Participants With ADPKD Phase 3
Completed NCT02225860 - Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Phase 2/Phase 3
Active, not recruiting NCT01616927 - Study of Lanreotide to Treat Polycystic Kidney Disease Phase 3
Completed NCT01430494 - Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT00346918 - Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT03949894 - Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease Phase 4
Recruiting NCT02925221 - Canadian Medical Assessment of JINARC™ Outcomes Registry
Completed NCT04689074 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
Terminated NCT02616055 - Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 Phase 2
Recruiting NCT06289998 - Study of Tamibarotene in Patients With ADPKD Phase 2
Completed NCT02112136 - Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD N/A
Recruiting NCT02115659 - Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT00309283 - Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Phase 3
Recruiting NCT06345755 - A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants Phase 1